Literature DB >> 34760964

Impact of body mass index on hepatocellular carcinoma recurrence after liver transplantation through long-term follow-up.

Nada El-Domiaty1,2, Faouzi Saliba1, Vincent Karam1, Rodolphe Sobesky1, Wafaa Ibrahim3, Eric Vibert1, Gabriella Pittau1, Khaled Amer4, Maysaa A Saeed2, Jihan A Shawky2, Daniel Cherqui1, René Adam1, Didier Samuel1.   

Abstract

BACKGROUND: Obesity is associated with increased oncological risk and outcomes but the evidence surrounding the effect of body mass index (BMI) on increased risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is still questionable. The purpose of this retrospective study of a large cohort of adult patients transplanted for HCC was to investigate the effect of BMI on the incidence of HCC recurrence and outcome.
METHODS: Data from 427 adult recipients transplanted for HCC between 2000 and 2017 were collected. Patients were classified at time of LT according to the World Health Organization BMI classification into 3 groups; group 1: BMI <25 (n=166), group 2: BMI 25-29.9 (n=150) and group 3: BMI ≥30 (n=111).
RESULTS: There were no significant changes of mean BMI overtime 26.8±5.0 kg/m2 at time of LT and 28.8±23.1 at 5 years. The recurrence rates of HCC after LT in the three groups were 19%, 16% and 17% respectively. The 5, 10 and 15-year recurrence free survival (RFS) rates were respectively 68.6%, 47.3% and 40.8% in group 1, 73.3%, 66.2% and 49.5% in group 2 and 68.8%, 57.5% and 47.7% in group 3 (log rank P=0.47).
CONCLUSIONS: Recipient BMI at time of transplant and during follow-up didn't impact the incidence of HCC recurrence nor long-term patient survival, irrespective to the status of the patients and their tumor characteristic at time of LT. The present study clearly confirms that obesity should not be considered, when selecting patients with HCC to LT, as a predictive factor of recurrence. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); body mass index (BMI); hepatocellular carcinoma recurrence (HCC recurrence); liver transplantation (LT); nutrition; obesity

Year:  2021        PMID: 34760964      PMCID: PMC8527412          DOI: 10.21037/hbsn.2020.04.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  28 in total

1.  Effect of race on outcome of orthotopic liver transplantation: a cohort study.

Authors:  Satheesh Nair; Joseph Eustace; Paul J Thuluvath
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics.

Authors:  Paul J Thuluvath; Hwan Y Yoo; Richard E Thompson
Journal:  Liver Transpl       Date:  2003-05       Impact factor: 5.799

3.  Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics.

Authors:  Adam S Bodzin; Keri E Lunsford; Daniela Markovic; Michael P Harlander-Locke; Ronald W Busuttil; Vatche G Agopian
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation.

Authors:  S Hwang; D-B Moon; C-S Ahn; K-H Kim; T-Y Ha; G-W Song; D-H Jung; G-C Park; H C Lee; Y S Lee; Y-H Chung; B A Abdulkarim; S-G Lee
Journal:  Transplant Proc       Date:  2013-10       Impact factor: 1.066

6.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

7.  Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.

Authors:  Shu-Guang Li; Zai-Yuan Ye; Zhong-Sheng Zhao; Hou-Quan Tao; Yuan-Yu Wang; Chun-Yu Niu
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Muscle mass predicts outcomes following liver transplantation.

Authors:  Andrea DiMartini; Ruy J Cruz; Mary Amanda Dew; Larissa Myaskovsky; Bret Goodpaster; Kristen Fox; Kevin H Kim; Paulo Fontes
Journal:  Liver Transpl       Date:  2013-11       Impact factor: 5.799

9.  Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo.

Authors:  G Rega; C Kaun; S Demyanets; S Pfaffenberger; K Rychli; P J Hohensinner; S P Kastl; W S Speidl; T W Weiss; J M Breuss; A Furnkranz; P Uhrin; J Zaujec; V Zilberfarb; M Frey; R Roehle; G Maurer; K Huber; J Wojta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-24       Impact factor: 8.311

10.  The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma.

Authors:  Yangkyu Lee; Hyunjin Park; Hyejung Lee; Jai Young Cho; Yoo-Seok Yoon; Young-Rok Choi; Ho-Seong Han; Eun Sun Jang; Jin-Wook Kim; Sook-Hyang Jeong; Soomin Ahn; Haeryoung Kim
Journal:  J Pathol Transl Med       Date:  2017-11-24
View more
  1 in total

1.  Metastasis of papillary thyroid cancer: does body mass index (BMI) is the key factor?

Authors:  Yuning Sun; Shaoyan Liu
Journal:  Gland Surg       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.